SCHEMBL6034666

SCHEMBL6034666

CCC(CC)c1nn(-c2ccc(Cl)cn2)cc1CCCOc1c(OC)cccc1OC(C)=O

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.36
PDE10A Q9Y233 2/20 0.33
PTPN1 P18031 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
ALDH1A1 P00352 2/20 0.32
ALOX5 P09917 2/20 0.32
MAPT P10636 2/20 0.32
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
SCN9A Q15858 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
FPR1 P21462 1/20 0.31
FPR2 P25090 1/20 0.31
PPARA Q07869 1/20 0.31
DRD4 P21917 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6221713 0.93 KDM4E (0.31) PPARGPTPN1SMN1; SMN2ALDH1A1MAPT
SCHEMBL6232363 0.93 PPARG (0.33) PPARGPDE10APTPN1PPARA
SCHEMBL6215845 0.92 PTPN1 (0.41) PPARGPTPN1SMN1; SMN2MAPTLMNA
SCHEMBL6217340 0.92 PPARG (0.38) PPARGPDE10APTPN1SMN1; SMN2ALDH1A1
SCHEMBL6216367 0.90 PTPN1 (0.33) PPARGPDE10APTPN1SMN1; SMN2ALDH1A1
SCHEMBL6232097 0.88 HCRTR1 (0.38) PTPN1SMN1; SMN2MAPTLMNASCN9A
SCHEMBL1633621 0.88 PPARG (0.48) PPARGSCN9AFPR1FPR2KDM4E
SCHEMBL6219261 0.86 PPARG (0.36) PPARGPDE10APTPN1SMN1; SMN2ALDH1A1
SCHEMBL6215721 0.85 PPARG (0.35) PPARGPDE10APTPN1ALOX5PPARA
SCHEMBL6218384 0.83 PPARG (0.33) PPARGPTPN1PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 PPARG 1037/4885PDE10A 3366/4885PTPN1 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.